Literature DB >> 30006844

Robotic transanal minimally invasive surgery (TAMIS) with the newest robotic surgical platform: a multi-institutional North American experience.

Shanglei Liu1,2, Toshiaki Suzuki3, Bryce W Murray4, Lisa Parry3, Craig S Johnson4, Santiago Horgan3, Sonia Ramamoorthy3, Samuel Eisenstein3.   

Abstract

BACKGROUND: Transanal minimally invasive surgery (TAMIS) offers intra-luminal full-thickness excision of rectal neoplasia. Robotic TAMIS (RT) allows for greater versatility in motion while operating in the limited space of the rectum. We present our experience with this technique in practice using the DaVinci Xi™ platform.
METHOD: This is a multi-institutional retrospective analysis for patient undergoing Robotic TAMIS for resection of rectal lesions at two tertiary referral hospitals in the United States. Morbidity, mortality, anatomic measurement, and final pathology were analyzed.
RESULTS: Thirty-four patients planned for Robotic TAMIS were identified. Average follow-up was 188 days. The average BMI was 29.5 ± 5.9. All patients had an American Society of Anesthesiologist (ASA) Class of 2 or greater and 21 (62%) were ASA 3 or greater. Rectal lesions located from 2 to 15 cm from the dentate line were successfully resected. Lesions up to 4.5 cm in the longest dimension were successfully resected. The average operative time was 100 ± 70 min, which correlated to a robotic console time of 76 ± 67 min. Patients were placed in Lithotomy in 32 (94%) cases and were prone in only 2 (6%) cases. There were no intraoperative complications or conversions to another technique. The only postoperative complication was a medically managed Clostridium difficile infection in 1 patient. Three patients were upstaged to T2 on final pathology and underwent successful formal resections. BMI was a statistically significant predictor of a longer operation.
CONCLUSIONS: With increased reach and operative range of motion, Robotic TAMIS is a safe and effective method for excising low-risk rectal neoplasia with a wide range of anatomical measurements. Higher BMI is a significant predictor of a longer and likely more challenging operation.

Entities:  

Keywords:  Anal cancer; Natural oriface surgery; Rectal cancer; Robotic surgery; TAMIS

Mesh:

Year:  2018        PMID: 30006844     DOI: 10.1007/s00464-018-6329-3

Source DB:  PubMed          Journal:  Surg Endosc        ISSN: 0930-2794            Impact factor:   4.584


  20 in total

1.  Local resection for early rectal tumours: Comparative study of transanal endoscopic microsurgery (TEM) versus posterior trans-sphincteric approach (Mason's operation).

Authors:  Guo-Le Lin; William C S Meng; Patrick Y Y Lau; Hui-Zhong Qiu; Andrew W C Yip
Journal:  Asian J Surg       Date:  2006-10       Impact factor: 2.767

Review 2.  Transanal endoscopic microsurgery: a systematic review.

Authors:  Philippa F Middleton; Leanne M Sutherland; Guy J Maddern
Journal:  Dis Colon Rectum       Date:  2005-02       Impact factor: 4.585

3.  Transanal endoscopic microsurgery for rectal neoplasms: experience of 300 consecutive cases.

Authors:  Marco Ettore Allaix; Alberto Arezzo; Mario Caldart; Federico Festa; Mario Morino
Journal:  Dis Colon Rectum       Date:  2009-11       Impact factor: 4.585

4.  [A system for a transanal endoscopic rectum operation].

Authors:  G Buess; F Hutterer; J Theiss; M Böbel; W Isselhard; H Pichlmaier
Journal:  Chirurg       Date:  1984-10       Impact factor: 0.955

5.  Cost analysis of transanal endoscopic microsurgery for rectal tumours.

Authors:  S Maslekar; S H Pillinger; A Sharma; A Taylor; J R T Monson
Journal:  Colorectal Dis       Date:  2007-03       Impact factor: 3.788

6.  Quality of life after transanal endoscopic microsurgery and total mesorectal excision in early rectal cancer.

Authors:  P G Doornebosch; R A E M Tollenaar; M P Gosselink; L P Stassen; C M Dijkhuis; W R Schouten; C J van de Velde; E J R de Graaf
Journal:  Colorectal Dis       Date:  2007-07       Impact factor: 3.788

7.  Technique of transanal endoscopic microsurgery.

Authors:  G Buess; K Kipfmüller; D Hack; R Grüssner; A Heintz; T Junginger
Journal:  Surg Endosc       Date:  1988       Impact factor: 4.584

8.  Surgical cure for early rectal carcinomas (T1). Transanal endoscopic microsurgery vs. anterior resection.

Authors:  G Winde; H Nottberg; R Keller; K W Schmid; H Bünte
Journal:  Dis Colon Rectum       Date:  1996-09       Impact factor: 4.585

9.  Transanal endoscopic microsurgery for the treatment of selected patients with distal rectal cancer: 15 years experience.

Authors:  M Guerrieri; M Baldarelli; L Organetti; F Grillo Ruggeri; G Mantello; S Bartolacci; E Lezoche
Journal:  Surg Endosc       Date:  2008-06-14       Impact factor: 4.584

10.  Transanal endoscopic micro-surgery (TEMS) for the management of large or sessile rectal adenomas: a review of the technique and indications.

Authors:  Savvas Papagrigoriadis
Journal:  Int Semin Surg Oncol       Date:  2006-05-04
View more
  4 in total

1.  Single-port robotic transanal minimally invasive surgery (SPR-TAMIS) approach to local excision of rectal tumors.

Authors:  S Liu; S R Kelley; K T Behm
Journal:  Tech Coloproctol       Date:  2020-07-06       Impact factor: 3.781

Review 2.  New Frontiers in Management of Early and Advanced Rectal Cancer.

Authors:  Jordan R Wlodarczyk; Sang W Lee
Journal:  Cancers (Basel)       Date:  2022-02-14       Impact factor: 6.639

3.  Comparison of advanced techniques for local excision of rectal lesions: a case series.

Authors:  Marisa E Schwab; Sophia Hernandez; Sarah Watanaskul; Hueylan Chern; Madhulika Varma; Ankit Sarin
Journal:  BMC Surg       Date:  2022-03-27       Impact factor: 2.102

4.  Clinical Robotic Surgery Association (India Chapter) and Indian rectal cancer expert group's practical consensus statements for surgical management of localized and locally advanced rectal cancer.

Authors:  S P Somashekhar; Avanish Saklani; Jagannath Dixit; Jagdish Kothari; Sandeep Nayak; O V Sudheer; Surender Dabas; Jagadishwar Goud; Venkatesh Munikrishnan; Pavan Sugoor; Prasanth Penumadu; C Ramachandra; Shilpa Mehendale; Akhil Dahiya
Journal:  Front Oncol       Date:  2022-10-04       Impact factor: 5.738

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.